查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1808837

基於 EV 的液體活體組織切片市場，按生物標記類型、按樣本類型、按應用、按最終用戶、按國家和地區分類 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率及預測

EV-Based Liquid Biopsy Market, By Biomarker Type, By Sample Type, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年基於 EV 的液體活體組織切片市場規模價值為 3.5523 億美元，2025 年至 2032 年的複合年成長率為 19.5%。

基於胞外囊泡的液體活體組織切片市場專注於利用細胞外載體 (EV) 作為非侵入性診斷工具。 EV 是細胞自然釋放到體液（例如血液、唾液和尿液）中的奈米級顆粒。這些囊泡攜帶生物訊息，例如 RNA、DNA、蛋白質和脂質，這些訊息反映了其來源細胞的狀態。這使得它們在檢測和監測疾病（尤其是癌症）方面具有重要價值。與傳統活體組織切片不同，基於 EV 的液體活體組織切片可以減輕患者的不適感，並能夠即時追蹤病情進展。它們也有利於檢測那些使用常規方法難以接近或監測的腫瘤。

人們對精準醫療、早期疾病檢測和微創診斷的興趣日益濃厚，推動了這項技術的普及。此外，與其他生物標記物相比，EVs 在血液循環中更穩定，從而提高了其可靠性。由於持續的研究、分離技術的改進以及更廣泛的臨床應用，EVs 市場正在不斷擴大。儘管存在一些挑戰，包括缺乏標準化和監管明確性，但基於 EVs 的液體活體組織切片正逐漸成為現代診斷領域具有相當前景的工具。

基於電動車的液體活體組織切片市場-市場動態

醫院內感染控制規程的不斷增加推動了對針頭銷毀器的需求。

基於細胞外囊泡 (EV) 的液體活體組織切片市場的一個關鍵利基促進因素是，使用細胞外囊泡 (EV) 生物標記進行非侵入性癌症監測的需求日益成長。傳統的癌症診斷通常依賴侵入性組織活體組織切片，這種活體組織切片可能帶來疼痛、風險高，而且並非總是可行，尤其是位於難以觸及部位的腫瘤。癌細胞釋放到體液中的 EV 攜帶著反映腫瘤狀態的遺傳和蛋白質組訊息。這使得臨床醫生能夠透過血液等簡單的體液樣本來追蹤癌症進展、治療反應或復發情況。

連續採樣技術能夠實現即時監測，無需患者反覆接受侵入性操作。此外，EVs 在血液循環中比遊離 DNA 等其他生物標記物更穩定，從而提高了結果的可靠性。隨著腫瘤學朝向個人化和精準化方向發展，基於 EVs 的活體組織切片正成為客製化治療方案的寶貴工具。在因患者健康狀況或腫瘤位置而無法進行組織活體組織切片的情況下，其作用尤其重要。日益成長的臨床需求持續推動 EVs 診斷技術的創新和投資。

基於電動車的液體活體組織切片市場—關鍵洞察

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 19.5%。

根據生物標記類型細分，預計 microRNA（miRNA）和信使 RNA（mRNA）將在 2024 年佔據最大市場佔有率

根據樣本類型細分，血液是 2024 年的主要樣本類型

根據應用細分，癌症診斷是 2024 年領先的應用

從地區來看，北美是 2024 年最大的收入來源

基於 EV 的液體活體組織切片市場-細分分析：

全球基於 EV 的液體活體組織切片市場根據生物標記類型、樣本類型、應用、最終用戶和地區進行細分。

根據生物標記類型，市場可分為四類：蛋白質、RNA（miRNA、mRNA 等）、DNA、脂質、其他。在基於 EV 的液體活體組織切片市場中，RNA（包括 microRNA (miRNA) 和信使 RNA (mRNA)）佔據主導地位。這種突出地位源自於 RNA 在反映起源細胞（尤其是癌細胞）遺傳活動方面所扮演的關鍵角色。 EV 攜帶穩定的 RNA 分子，為基因表現模式提供寶貴的見解，從而實現早期疾病的檢測和監測。

與其他生物分子相比，RNA生物標記具有較高的特異性和敏感性，這對於準確的診斷和預後至關重要。尤其是miRNA，它調節各種細胞過程，並與腫瘤進展相關，使其成為液體活體組織切片的有力指標。此外，RNA定序和分析技術的進步提高了可靠地檢測和定量EV相關RNA的能力。個人化醫療日益受到關注，這進一步支持了RNA生物標記的應用，因為它們有助於根據分子譜量身定做治療方案。儘管從EV中分離純RNA面臨挑戰，但正在進行的研究正在克服這些障礙，鞏固了RNA作為該市場關鍵驅動力的地位。

根據應用，市場分為五類：癌症診斷、傳染病、神經系統疾病、心血管疾病和其他。癌症診斷是EV液體活體組織切片市場中最主要的樣本類型細分市場。這種主導地位源於對早期、準確、微創的癌症檢測和監測方法的迫切需求。腫瘤細胞釋放的細胞外囊泡攜帶蛋白質、RNA和DNA等分子特徵，可提供有關腫瘤存在、進展和治療反應的即時資訊。與傳統的組織活體組織切片不同，EV液體活體組織切片可以透過簡單的血液或體液樣本進行持續監測，從而減少患者不適並實現更早的干涉。

全球癌症負擔的不斷上升以及對個人化醫療的日益重視，進一步推動了基於EV的診斷技術在腫瘤學中的應用。此外，這些液體活體組織切片有助於檢測那些難以透過常規方法接近或監測的腫瘤。研究和臨床試驗持續驗證EV生物標記在癌症檢測中的有效性，這使得此樣本類型成為市場的主要成長動力。雖然傳染病和神經系統疾病等其他樣本類型正在興起，但癌症診斷目前仍是基於EV的液體活體組織切片開發和商業化的重點。

電動汽車液體活體組織切片市場—地理洞察

在北美，得益於先進的醫療基礎設施和創新診斷技術的早期應用，基於囊泡的液體活體組織切片市場發展勢頭強勁。該地區受益於由學術機構、生物技術公司和專注於癌症診斷的政府資助計畫支持的強大研究生態系統。醫療保健專業人士對細胞外囊泡在非侵入性疾病檢測和監測中的臨床價值的認知日益加深。完善的監管框架和正在進行的臨床試驗促進了基於囊泡的檢測與臨床實踐的整合。

美國在基於囊泡的液體活體組織切片市場中處於領先地位，這得益於其先進的醫療基礎設施和對早期癌症檢測的高度重視。美國強大的科研生態系統，涵蓋領先的學術機構和生物終端用戶公司，促進了診斷技術的持續創新。臨床醫生和患者對非侵入性診斷方法的日益青睞，加速了基於囊泡的液體活體組織切片的應用，該技術可以即時洞察病情進展和治療反應。美國食品藥物管理局 (FDA) 在監管這些新興技術方面發揮關鍵作用，確保其符合安全性和有效性標準。然而，挑戰依然存在，包括需要製定囊泡分離和分析的標準化方案。

基於 EV 的液體活體組織切片市場-競爭格局：

基於囊泡的液體活體組織切片市場的競爭格局由眾多成熟的生物終端用戶公司和專注於細胞外囊泡技術的創新新創公司共同塑造。 Exosome Diagnostics、賽默飛世爾科技和Qiagen等公司是產業翹楚，它們利用自身強大的研發實力和全球影響力，推動基於囊泡的診斷技術發展。 Bio-Techne Corporation和NanoView Biosciences也透過囊泡檢測和表徵技術創新取得了重大進展。同時，System Biosciences (SBI)、美天旎生物技術公司和AMSBIO也正在提供專業的囊泡分離和分析試劑盒。

Exosomics SpA、Codiak BioSciences 和 VivaZome Therapeutics 等新興公司正在透過開發基於 EV 的新型平台（專門針對腫瘤學和個人化醫療）加劇競爭。市場瞬息萬變，策略合作、研究夥伴關係和臨床驗證在塑造競爭地位方面發揮關鍵作用。隨著監管途徑日益清晰，這些公司可望擴大在臨床領域的佈局。

最新動態：

2024年10月，QIAGEN擴展了其自動化液體活體組織切片產品組合，以增強其在腫瘤學、產前護理和器官移植領域的應用。全新升級的ccfDNA試劑盒，包含適用於EZ1和2儀器的尿液檢測方案，旨在改善癌症研究的液體活體組織切片工作流程。 QIAsymphony DSP循環DNA和Maxi試劑盒可為下游應用提供高品質的cfDNA。

目錄

第 1 章：基於 EV 的液體活體組織切片市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • EV 液體活體組織切片市場片段（按生物標記類型）
    • EV 液體活體組織切片市場（按樣本類型）
    • 基於 EV 的液體活體組織切片市場片段（按應用）
    • EV 液體活體組織切片市場片段（按最終用戶）
    • 電動汽車液體活體組織切片市場（按國家/地區）
    • 電動汽車液體活體組織切片市場（按地區）
  • 競爭洞察

第3章：基於 EV 的液體活體組織切片關鍵市場趨勢

  • 基於電動車的液體活體組織切片市場促進因素
    • 市場促進因素的影響分析
  • 基於EV的液體活體組織切片市場限制
    • 市場限制的影響分析
  • 基於EV的液體切片市場機遇
  • 基於EV的液體切片市場未來趨勢

第4章：基於電動車的液體活體組織切片產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：基於電動車的液體活體組織切片市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：基於 EV 的液體活體組織切片市場格局

  • 2024年EV液體切片市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第 7 章：基於 EV 的液體活體組織切片市場 - 按生物標記類型

  • 概述
    • 按生物標記類型分類的細分市場佔有率分析
    • 蛋白質
    • RNA（miRNA、mRNA等）
    • 脫氧核糖核酸
    • 脂質
    • 其他

第 8 章：基於 EV 的液體活體組織切片市場 - 按樣本類型

  • 概述
    • 依樣本類型進行細分佔有率分析
    • 血
    • 尿
    • 唾液
    • 腦脊髓液
    • 其他

第 9 章：基於 EV 的液體活體組織切片市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 癌症診斷
    • 傳染病
    • 神經系統疾病
    • 心血管疾病
    • 其他

第 10 章：基於 EV 的液體活體組織切片市場 - 按最終用戶

  • 概述
    • 依樣本類型進行細分佔有率分析
    • 醫院和診所
    • 研究機構
    • 診斷實驗室
    • 生物製藥公司
    • 其他

第 11 章：基於 EV 的液體活體組織切片市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美EV液體切片主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依生物標記類型）
    • 北美市場規模和預測（按樣本類型）
    • 北美市場規模和預測（按應用）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲EV液體活體組織切片主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依生物標記類型）
    • 歐洲市場規模及預測（依樣本類型）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區基於EV的液體活體組織切片主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依生物標記類型）
    • 亞太地區市場規模及預測（依樣本類型）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲基於EV的液體活體組織切片關鍵製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依生物標記類型）
    • 拉丁美洲市場規模及預測（依樣本類型）
    • 拉丁美洲市場規模及預測（按應用）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲基於 EV 的液體活體組織切片關鍵製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依生物標記類型）
    • MEA 市場規模及預測（依樣品類型）
    • MEA 市場規模及預測（按應用）
    • MEA 市場規模及預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：關鍵供應商分析-基於 EV 的液體活體組織切片產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Exosome Diagnostics
    • Bio-Techne Corporation
    • Thermo Fisher Scientific
    • NanoView Biosciences
    • System Biosciences (SBI)
    • Qiagen
    • Norgen Biotek Corp.
    • BioVision Inc.
    • Miltenyi Biotec
    • Creative Biolabs
    • AMSBIO
    • Exosomics SpA
    • NX Pharmagen
    • VivaZome Therapeutics
    • Aethlon Medical
    • Evox Therapeutics
    • Capricor Therapeutics
    • Codiak BioSciences
    • Anjarium Biosciences
    • HansaBioMed Life Sciences

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5501

EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.

The EV-based liquid biopsy market focuses on the use of extracellular vehicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry biological information, like RNA, DNA, proteins, and lipids, that reflects the state of their originating cells. This makes them valuable for detecting and monitoring diseases, especially cancers. Unlike traditional biopsies, EV-based liquid biopsies reduce patient discomfort and enable real-time tracking of disease progression. They are also advantageous for detecting tumors that are difficult to access or monitor using conventional methods.

Growing interest in precision medicine, early disease detection, and less invasive diagnostics is driving the adoption of this technology. Additionally, EVs are more stable in circulation compared to other biomarkers, which enhances their reliability. The market is expanding due to ongoing research, improved isolation techniques, and broader clinical applications. Despite some challenges, including a lack of standardization and regulatory clarity, EV-based liquid biopsy is emerging as a promising tool in modern diagnostics.

EV-Based Liquid Biopsy Market- Market Dynamics

Rising hospital-acquired infection control protocols drive demand for needle destroyers.

A key niche driver for the EV-based liquid biopsy market is the growing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be painful, risky, and not always feasible, especially for tumors in inaccessible locations. EVs, released by cancer cells into body fluids, carry genetic and proteomic information that mirrors the tumor's state. This enables clinicians to track cancer progression, therapeutic response, or recurrence with simple fluid samples like blood.

The ability to perform serial sampling offers real-time monitoring without subjecting patients to repeated invasive procedures. Additionally, EVs are more stable in circulation than other biomarkers like cell-free DNA, improving result reliability. As oncology shifts toward personalized and precision-based approaches, EV-based biopsies are becoming a valuable tool for tailoring treatments. Their role is particularly significant in cases where tissue biopsy is not possible due to the patient's health or tumor location. This rising clinical demand continues to propel innovation and investment in EV-based diagnostics.

EV-Based Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.5% over the forecast period (2025-2032)

Based on Biomarker Type segmentation, microRNA (miRNA) and messenger RNA (mRNA), were predicted to show maximum market share in the year 2024

Based on Sample Type segmentation, Blood was the leading Sample Type in 2024

Based on Application segmentation, Cancer diagnostics was the leading Application in 2024

Based on region, North America was the leading revenue generator in 2024

EV-Based Liquid Biopsy Market- Segmentation Analysis:

The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.

The market is divided into four categories based on Biomarker Type. Proteins, RNA (miRNA, mRNA, etc.), DNA, Lipids, Others. Among the biomarker types in the EV-based liquid biopsy market, RNA, including microRNA (miRNA) and messenger RNA (mRNA), emerges as the most dominant segment. This prominence is due to the critical role RNA plays in reflecting the genetic activity of originating cells, especially cancer cells. EVs carry stable RNA molecules that provide valuable insights into gene expression patterns, enabling early disease detection and monitoring.

Compared to other biomolecules, RNA biomarkers offer high specificity and sensitivity, which are essential for accurate diagnosis and prognosis. miRNAs, in particular, regulate various cellular processes and have been linked to tumor progression, making them powerful indicators in liquid biopsies. Additionally, advances in RNA sequencing and analysis technologies have improved the ability to detect and quantify EV-associated RNAs reliably. The growing focus on personalized medicine further supports the use of RNA biomarkers, as they help tailor treatments based on molecular profiles. Despite challenges in isolating pure RNA from EVs, ongoing research is overcoming these obstacles, cementing RNA's position as a key driver in this market.

The market is divided into five categories based on Application: Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Cancer diagnostics is the most dominant Sample Type segment in the EV-based liquid biopsy market. This dominance stems from the critical need for early, accurate, and minimally invasive methods to detect and monitor cancer. Extracellular vesicles released by tumor cells carry molecular signatures such as proteins, RNA, and DNA that provide real-time information about tumor presence, progression, and response to treatment. Unlike traditional tissue biopsies, EV-based liquid biopsies allow for continuous monitoring through simple blood or body fluid samples, reducing patient discomfort and enabling earlier intervention.

The rising global cancer burden and increasing emphasis on personalized medicine have further driven the adoption of EV-based diagnostics in oncology. Additionally, these liquid biopsies help detect tumors that are difficult to access or monitor through conventional methods. Research and clinical trials continue to validate the efficacy of EV biomarkers in cancer detection, making this Sample Type the primary growth driver for the market. While other Sample Types like infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the focal point of EV-based liquid biopsy development and commercialization.

EV-Based Liquid Biopsy Market- Geographical Insights

In North America, the EV-based liquid biopsy market is experiencing strong momentum due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. The region benefits from a robust research ecosystem supported by academic institutions, biotech companies, and government funding initiatives focused on cancer diagnostics. There is a growing awareness among healthcare professionals about the clinical value of extracellular vesicles in non-invasive disease detection and monitoring. The integration of EV-based tests into clinical practice is facilitated by the presence of well-established regulatory frameworks and ongoing clinical trials.

The United States is at the forefront of the EV-based liquid biopsy market, driven by its advanced healthcare infrastructure and strong emphasis on early cancer detection. The country's robust research ecosystem, encompassing leading academic institutions and bioEnd-user firms, fosters continuous innovation in diagnostic technologies. A growing preference for non-invasive diagnostic methods among clinicians and patients has accelerated the adoption of EV-based liquid biopsies, which offer real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these emerging technologies, ensuring safety and efficacy standards are met. However, challenges persist, including the need for standardized protocols for EV isolation and analysis.

EV-Based Liquid Biopsy Market- Competitive Landscape:

The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established bioend-user firms and innovative startups focused on extracellular vesicle technologies. Companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen are prominent players, leveraging their strong research capabilities and global reach to advance EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant strides through technological innovations in EV detection and characterization. Meanwhile, System Biosciences (SBI), Miltenyi Biotec, and AMSBIO are contributing specialized EV isolation and analysis kits.

Emerging companies like Exosomics S.p.A, Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms tailored for oncology and personalized medicine. The market is highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing a key role in shaping competitive positioning. As regulatory pathways become clearer, these companies are expected to expand their presence in clinical settings.

Recent Developments:

In October 2024, QIAGEN expanded its automated liquid biopsy portfolio to enhance oncology, prenatal care, and organ transplant applications. The new ccfDNA Kit upgrade with a urine protocol for EZ1 and 2 instruments is designed to improve liquid biopsy workflows for cancer research. The QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for downstream applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Exosome Diagnostics
  • Bio-Techne Corporation
  • Thermo Fisher Scientific
  • NanoView Biosciences
  • System Biosciences (SBI)
  • Qiagen
  • Norgen Biotek Corp.
  • BioVision Inc.
  • Miltenyi Biotec
  • Creative Biolabs
  • AMSBIO
  • Exosomics S.p.A
  • NX Pharmagen
  • VivaZome Therapeutics
  • Aethlon Medical
  • Evox Therapeutics
  • Capricor Therapeutics
  • Codiak BioSciences
  • Anjarium Biosciences
  • HansaBioMed Life Sciences

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Proteins
  • RNA (miRNA, mRNA, etc.)
  • DNA
  • Lipids
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Blood
  • Urine
  • Saliva
  • Cerebrospinal Fluid
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer Diagnostics
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Diseases
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Biopharmaceutical Companies
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. EV-Based Liquid Biopsy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. EV-Based Liquid Biopsy Market Snippet by Biomarker Type
    • 2.1.2. EV-Based Liquid Biopsy Market Snippet by Sample Type
    • 2.1.3. EV-Based Liquid Biopsy Market Snippet by Application
    • 2.1.4. EV-Based Liquid Biopsy Market Snippet by End-user
    • 2.1.5. EV-Based Liquid Biopsy Market Snippet by Country
    • 2.1.6. EV-Based Liquid Biopsy Market Snippet by Region
  • 2.2. Competitive Insights

3. EV-Based Liquid Biopsy Key Market Trends

  • 3.1. EV-Based Liquid Biopsy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. EV-Based Liquid Biopsy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. EV-Based Liquid Biopsy Market Opportunities
  • 3.4. EV-Based Liquid Biopsy Market Future Trends

4. EV-Based Liquid Biopsy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. EV-Based Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. EV-Based Liquid Biopsy Market Landscape

  • 6.1. EV-Based Liquid Biopsy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. EV-Based Liquid Biopsy Market - By Biomarker Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biomarker Type, 2024 & 2032 (%)
    • 7.1.2. Proteins
    • 7.1.3. RNA (miRNA, mRNA, etc.)
    • 7.1.4. DNA
    • 7.1.5. Lipids
    • 7.1.6. Others

8. EV-Based Liquid Biopsy Market - By Sample Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 8.1.2. Blood
    • 8.1.3. Urine
    • 8.1.4. Saliva
    • 8.1.5. Cerebrospinal Fluid
    • 8.1.6. Others

9. EV-Based Liquid Biopsy Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Cancer Diagnostics
    • 9.1.3. Infectious Diseases
    • 9.1.4. Neurological Disorders
    • 9.1.5. Cardiovascular Diseases
    • 9.1.6. Others

10. EV-Based Liquid Biopsy Market - By End-user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Research Institutes
    • 10.1.4. Diagnostic Laboratories
    • 10.1.5. Biopharmaceutical Companies
    • 10.1.6. Others

11. EV-Based Liquid Biopsy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. EV-Based Liquid Biopsy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. EV-Based Liquid Biopsy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. EV-Based Liquid Biopsy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. EV-Based Liquid Biopsy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. EV-Based Liquid Biopsy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- EV-Based Liquid Biopsy Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Exosome Diagnostics
    • 12.2.2. Bio-Techne Corporation
    • 12.2.3. Thermo Fisher Scientific
    • 12.2.4. NanoView Biosciences
    • 12.2.5. System Biosciences (SBI)
    • 12.2.6. Qiagen
    • 12.2.7. Norgen Biotek Corp.
    • 12.2.8. BioVision Inc.
    • 12.2.9. Miltenyi Biotec
    • 12.2.10. Creative Biolabs
    • 12.2.11. AMSBIO
    • 12.2.12. Exosomics S.p.A
    • 12.2.13. NX Pharmagen
    • 12.2.14. VivaZome Therapeutics
    • 12.2.15. Aethlon Medical
    • 12.2.16. Evox Therapeutics
    • 12.2.17. Capricor Therapeutics
    • 12.2.18. Codiak BioSciences
    • 12.2.19. Anjarium Biosciences
    • 12.2.20. HansaBioMed Life Sciences

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us